奥西替尼治疗EGFR T790M突变的晚期肺腺癌1例
| 作者: |
1刘洪伯,
1柳江
1 新疆维吾尔自治区人民医院肿瘤科，乌鲁木齐 830000 |
| 通讯: |
柳江
Email: Liujiang@csco.org.cn |
| DOI: | 10.3978/j.issn.2095-6959.2020.01.041 |
摘要
1例表皮生长因子受体(epithelial growth factor receptor，EGFR)基因第19外显子敏感缺失突变肺腺癌患者接受第一代EGFR抑制剂(tyrosine kinase inhibitors，TKIs)治疗后，无进展生存期(progression-free survival，PFS)达33个月，此后病情进展，患者出现脑转移，肺内病灶增大，行经皮肺肿物穿刺活检术，再次行肿瘤组织标本EGFR基因检测，提示20外显子T790M突变，予以奥希替尼靶向治疗34个月，2019年10月8日患者仍未达到PFS。奥希替尼治疗T790M突变肺腺癌，疗效确切、安全性良好，该例患者主要不良反应为QTc间期延长。
关键词：
非小细胞肺癌；表皮生长因子受体抑制剂；T790M；吉非替尼；奥西替尼
A case of advanced lung adenocarcinoma with EGFR T790M mutation treated with osimertinib
CorrespondingAuthor: Liu Jiang Email: Liujiang@csco.org.cn
DOI: 10.3978/j.issn.2095-6959.2020.01.041
Abstract
One case of lung adenocarcinoma with epithelial growth factor receptor (EGFR) gene exon 19 sensitive deletion mutant was treated with the first generation of EGFR-TKIs, its progression-free survival (PFS) reached 33 months. The patient progressed and developed brain metastasis, the lung lesion increased, and the percutaneous lung mass biopsy was performed. The EGFR gene test of the tumor tissue specimen was again performed, which suggested that the T790M mutation of exon 20. The target treatment of osimertinib was obtained for 34 months, the PFS has not been reached up to the submission. Osimertinib in the treatment of lung adenocarcinoma with T790M mutant had good efficacy and safety, the main adverse reaction of this patient was prolonged QTc interval.
Keywords：
non-small cell lung cancer; epidermal growth factor receptor-tyrosine kinase inhibitor; T790M; gefitinib; osimertinib